Rhonda Farnum Sells 13,314 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total transaction of $226,737.42. Following the sale, the senior vice president owned 213,476 shares in the company, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Price Performance

TBPH opened at $17.02 on Friday. The firm has a market cap of $883.68 million, a P/E ratio of 16.85 and a beta of 0.25. Theravance Biopharma, Inc. has a 1-year low of $13.08 and a 1-year high of $21.03. The company has a 50 day simple moving average of $16.96 and a two-hundred day simple moving average of $16.40.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The firm had revenue of $20.73 million for the quarter, compared to the consensus estimate of $22.49 million. Equities analysts anticipate that Theravance Biopharma, Inc. will post 1.56 earnings per share for the current year.

Institutional Trading of Theravance Biopharma

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its position in shares of Theravance Biopharma by 51.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,408 shares during the last quarter. First Trust Advisors LP increased its position in Theravance Biopharma by 19.5% in the first quarter. First Trust Advisors LP now owns 18,959 shares of the biopharmaceutical company’s stock worth $308,000 after purchasing an additional 3,099 shares during the last quarter. SG Americas Securities LLC raised its stake in Theravance Biopharma by 25.8% during the first quarter. SG Americas Securities LLC now owns 18,256 shares of the biopharmaceutical company’s stock valued at $296,000 after purchasing an additional 3,747 shares in the last quarter. Wellington Management Group LLP raised its stake in Theravance Biopharma by 3.4% during the second quarter. Wellington Management Group LLP now owns 113,481 shares of the biopharmaceutical company’s stock valued at $1,929,000 after purchasing an additional 3,781 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in Theravance Biopharma by 32.9% during the first quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 4,463 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several research analyst reports. JonesTrading downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and lifted their target price for the company from $15.00 to $17.00 in a research note on Tuesday, July 7th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. Finally, Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Eight analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Theravance Biopharma has an average rating of “Hold” and an average price target of $19.40.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.